Active MMP-8 point-of-care (PoC)/chairside enzyme-test as an adjunctive tool for early and real-time diagnosis of peri-implantitis

Clin Exp Dent Res. 2022 Apr;8(2):485-496. doi: 10.1002/cre2.537. Epub 2022 Feb 3.

Abstract

Objective: The aim of this study was to investigate the utility of the active matrix metalloproteinase (aMMP-8)-point-of-care (PoC) test as a quantitative real-time chair-side diagnostic tool for peri-implant diagnosis, as well as assess the potentially developing and ongoing risk relative to the traditional clinical methods.

Background: Current peri-implant and periodontal disease diagnoses rely on clinical and radiological examinations. This case-control study investigated the applicability of aMMP-8-PoC immunotest for quantitative real-time diagnosis and monitoring of dental implants in health and disease.

Methods: Sixty-eight patients visiting a specialist clinic for maintenance following dental implant placement underwent assessment of their peri-implant health. aMMP-8-PoC peri-implant sulcular fluid (PISF) lateral-flow immunotests were performed using ImplantSafe® technology quantitated by ORALyzer®. In addition, the PISF samples were analyzed for total MMP-8, calprotectin, and interleukin (IL)-6 by enzyme-linked immunosorbent assays (ELISA), aMMP-8 by western immunoblot, and MMP-2 and MMP-9 by gelatin zymography.

Results: The aMMP-8-PoC test promptly recorded and reflected peri-implant disease, differentiating it clearly from health. X-ray findings (bone loss > 2 mm), peri-implant pocket depth ≥ 3 mm, and bleeding on probing were significantly more prevalent among implants positive for the aMMP-8-PoC test. aMMP-8/ORALyzer analysis was more precise in recording disease than total MMP-8, calprotectin, IL-6, MMP-2, and MMP-9.

Conclusions: The aMMP-8-PoC test can be conveniently implemented to alert for and detect active collagenolysis affecting peri-implant tissues, both in the early and advanced stages of the disease. Active and fragmented MMP-8 exhibits a strong and significant association with peri-implantitis as compared to total MMP-8 and other biomarkers and can be utilized as the POC/chairside biomarker of choice in the new classification of peri-implantitis.

Keywords: biomarkers; diagnosis; matrix metalloproteinase 8; peri-implantitis; preventive medicine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / analysis
  • Case-Control Studies
  • Dental Implants* / adverse effects
  • Gingival Crevicular Fluid / chemistry
  • Humans
  • Leukocyte L1 Antigen Complex / analysis
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 8 / analysis
  • Matrix Metalloproteinase 8 / metabolism
  • Matrix Metalloproteinase 9
  • Peri-Implantitis* / diagnosis
  • Point-of-Care Systems

Substances

  • Biomarkers
  • Dental Implants
  • Leukocyte L1 Antigen Complex
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 8
  • Matrix Metalloproteinase 9